GLP-1 Receptor Agonism

GLP-1 Receptor Binding and Activation

GLP-1 receptor agonists bind the large N-terminal extracellular domain of GLP-1R with high affinity, often in the nanomolar to sub-nanomolar range. Binding triggers a conformational rearrangement in the receptor's seven transmembrane helices that allosterically activates the intracellular Gs protein subunit. Gs then stimulates adenylyl cyclase, which catalyses the conversion of ATP to cyclic AMP (cAMP). Elevated intracellular cAMP in turn activates protein kinase A (PKA), which phosphorylates a range of downstream substrates depending on the cell type. This Gs–cAMP–PKA cascade is the central signalling logic from which all GLP-1R downstream effects derive; some effects also involve exchange proteins directly activated by cAMP (EPACs), particularly in beta cells.

Glucose-Dependent Insulin Secretion

In pancreatic beta cells, GLP-1R activation elevates cAMP, which activates PKA. PKA phosphorylates voltage-gated calcium channels (VGCCs) in the beta cell membrane, increasing their open probability and driving calcium influx. The resulting rise in intracellular Ca²⁺ triggers the exocytosis of insulin-containing secretory vesicles. Critically, this mechanism is glucose-dependent: it requires that elevated intracellular glucose has already driven closure of ATP-sensitive potassium (K_ATP) channels and partial depolarisation of the cell membrane. In euglycaemic or hypoglycaemic conditions, the K_ATP channels remain open, the membrane cannot adequately depolarise, and GLP-1R stimulation cannot efficiently trigger the calcium cascade. This glucose-dependence means GLP-1 receptor agonists carry a fundamentally low intrinsic risk of hypoglycaemia — a safety advantage that distinguishes them from sulfonylureas, which force insulin release regardless of prevailing glucose levels.

Glucagon Suppression

GLP-1R is also expressed on pancreatic alpha cells, and its activation here suppresses glucagon secretion. This effect is physiologically important because glucagon drives hepatic gluconeogenesis — the liver's production of new glucose from non-carbohydrate substrates — and stimulates hepatic glycogenolysis. In type 2 diabetes, alpha cell glucagon secretion is inappropriately elevated, contributing substantially to fasting and postprandial hyperglycaemia. GLP-1R agonism suppresses this excess glucagon release, thereby reducing hepatic glucose output. This mechanism works in parallel with the beta cell insulin-stimulating effect, achieving glucose lowering through two complementary routes simultaneously. Notably, glucagon suppression by GLP-1 agonists is also glucose-dependent, diminishing during hypoglycaemia so that the counterregulatory glucagon response to low blood glucose is preserved.

Gastric Emptying Delay

GLP-1R is expressed in the enteric nervous system and on vagal afferent nerve terminals in the gut wall. Activation of these peripheral receptors slows gastric motility and delays the transit of food from the stomach into the duodenum — a process known as delayed gastric emptying or gastroparesis-like slowing at pharmacological doses. By reducing the rate at which ingested carbohydrates reach the small intestine and enter the bloodstream, this mechanism blunts postprandial glucose excursions, contributing an additional glycaemic benefit beyond the pancreatic effects. Slower gastric emptying also prolongs the physical sensation of gastric distension after eating, generating an earlier and more sustained feeling of fullness. This peripheral satiety signal complements the central appetite effects described in the next step. At the high doses used in obesity treatment (e.g. semaglutide 2.4 mg), slowed gastric emptying can cause nausea and vomiting, which are the most common side effects of GLP-1 agonist therapy.

Central Appetite Suppression

GLP-1R is expressed in multiple brain regions critically involved in energy homeostasis. In the hypothalamus, receptors are concentrated in the arcuate nucleus (ARC) and paraventricular nucleus (PVN). In the brainstem, the nucleus of the solitary tract (NTS) — which processes vagal afferent signals from the gut — is a dense site of GLP-1R expression. Agonism in the ARC suppresses the activity of NPY/AgRP neurons, which normally drive hunger and food-seeking behaviour, while simultaneously increasing the activity of POMC/CART neurons, which signal satiety and reduce appetite. The net effect is a sustained reduction in caloric intake that persists well beyond any meal-related satiety. Beyond homeostatic appetite circuits, GLP-1R agonism also modulates the mesolimbic dopamine system — the reward circuitry centred on the ventral tegmental area (VTA) and nucleus accumbens. Evidence from both rodent studies and clinical observations suggests that GLP-1 agonists dampen the reward value of food, reducing hedonic eating, food cravings, and potentially addictive food behaviours. This central mechanism is considered the primary driver of the substantial weight loss (15–25% body weight) seen with high-dose semaglutide and tirzepatide.

Cardiovascular and Renal Effects

GLP-1R is expressed in cardiac myocytes, vascular endothelial cells, smooth muscle cells, and renal tubular epithelium. Agonism at these sites produces a range of direct and indirect cardioprotective effects. In the vasculature, GLP-1R activation promotes vasodilation, reduces endothelial inflammation, and decreases oxidative stress in arterial walls. In the kidney, GLP-1R activation increases natriuresis (sodium excretion), contributing to modest reductions in blood pressure and potentially to renal protection. In the heart, direct GLP-1R signalling appears cardioprotective in ischaemia-reperfusion models, and retrospective analyses suggested cardioprotection before prospective trials confirmed it. The SELECT trial — a cardiovascular outcomes trial enrolling over 17,000 non-diabetic overweight and obese adults with established cardiovascular disease — demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg versus placebo, establishing that cardiovascular benefit is independent of glycaemic effects. The mechanisms underlying this clinical benefit likely include reduced systemic inflammation, improved endothelial function, lower blood pressure, and weight loss, though the relative contributions remain under investigation.